The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Human Tumor Atlas Network

Research output: Contribution to journalReview articlepeer-review

162 Scopus citations

Abstract

Crucial transitions in cancer—including tumor initiation, local expansion, metastasis, and therapeutic resistance—involve complex interactions between cells within the dynamic tumor ecosystem. Transformative single-cell genomics technologies and spatial multiplex in situ methods now provide an opportunity to interrogate this complexity at unprecedented resolution. The Human Tumor Atlas Network (HTAN), part of the National Cancer Institute (NCI) Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types. This effort complements both ongoing efforts to map healthy organs and previous large-scale cancer genomics approaches focused on bulk sequencing at a single point in time. Generating single-cell, multiparametric, longitudinal atlases and integrating them with clinical outcomes should help identify novel predictive biomarkers and features as well as therapeutically relevant cell types, cell states, and cellular interactions across transitions. The resulting tumor atlases should have a profound impact on our understanding of cancer biology and have the potential to improve cancer detection, prevention, and therapeutic discovery for better precision-medicine treatments of cancer patients and those at risk for cancer. The Human Tumor Atlas Network outlines their ambitious plan to generate 3D, single-cell, multiparametric, and longitudinal maps of diverse tumor types.

Original languageEnglish (US)
Pages (from-to)236-249
Number of pages14
JournalCell
Volume181
Issue number2
DOIs
StatePublished - Apr 16 2020

Bibliographical note

Funding Information:
We thank Jennifer Beane-Ebel for critical reading of the manuscript. This work is supported by the National Cancer Institute Cancer Moonshot under awards U24 CA233243, U2C CA233195, U2C CA233238, U2C CA233254, U2C CA233262, U2C CA233280, U2C CA233284, U2C CA233285, U2C CA233291, U2C CA233303, and U2C CA233311. The Lung Pre-Cancer Atlas is partly supported by funding from Janssen Research & Development LLC (principal investigator [PI]: S.A.M.), Johnson & Johnson (PI: S.A.M.), and a Stand Up To Cancer (SU2C)-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Research Grant (SU2C-AACR-DT23-17 to S.M.D. and A.E.S.). SU2C is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. The Human Tumor Atlas Pilot Project is supported by federal funds from the NIH National Cancer Institute (task order no. HHSN261100039 under contract no. HHSN261201500003I). A.R. is an investigator of the Howard Hughes Medical Institute. A.R. and O.R.R. are supported by the Klarman Cell Observatory at the Broad Institute. D.S. is funded by an Early Postdoc Mobility fellowship (no. P2ZHP3_181475) from the Swiss National Science Foundation. A.R. is a founder of and equity holder in Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and a scientific advisory board (SAB) member of Syros Pharmaceuticals, ThermoFisher Scientific, Asimov, and NeoGene Therapeutics. A.K.S. has received compensation for consulting for and being on the SAB of Honeycomb Biotechnologies, Cellarity, Cogen Therapeutics, and Dahlia Biosciences. O.R.R. A.K.S. and A.R. are co-inventors on patent applications filed by the Broad Institute to inventions relating to single-cell genomics, such as in PCT/US2018/060860 and US provisional application no. 62/745,259. J.W.G. has licensed technologies to Abbott Diagnostics and Danaher and has ownership positions in PDX Pharmaceuticals and Convergent Genomics. He serves as an advisor to New Leaf Ventures and receives private-sector research support from Zeiss, ThermoFisher, Danaher, Micron, PDX Pharmaceuticals, and Quantitative Imaging. C.I.D. receives research support from Bristol-Myers Squibb. S.S. is a consultant for RareCyte, Inc. A.S. is an employee of Johnson & Johnson. S.A.M. has commercial research grants from Johnson & Johnson. P.K.S. is a member of the SAB or board of directors of and has equity in Glencoe Software and RareCyte Inc. which create software and instruments for tissue imaging.

Funding Information:
We thank Jennifer Beane-Ebel for critical reading of the manuscript. This work is supported by the National Cancer Institute Cancer Moonshot under awards U24 CA233243 , U2C CA233195 , U2C CA233238 , U2C CA233254 , U2C CA233262 , U2C CA233280 , U2C CA233284 , U2C CA233285 , U2C CA233291 , U2C CA233303 , and U2C CA233311 . The Lung Pre-Cancer Atlas is partly supported by funding from Janssen Research & Development LLC (principal investigator [PI]: S.A.M.), Johnson & Johnson (PI: S.A.M.), and a Stand Up To Cancer (SU2C)-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Research Grant ( SU2C-AACR-DT23-17 to S.M.D. and A.E.S.). SU2C is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. The Human Tumor Atlas Pilot Project is supported by federal funds from the NIH National Cancer Institute (task order no. HHSN261100039 under contract no. HHSN261201500003I ). A.R. is an investigator of the Howard Hughes Medical Institute. A.R. and O.R.R. are supported by the Klarman Cell Observatory at the Broad Institute . D.S. is funded by an Early Postdoc Mobility fellowship (no. P2ZHP3_181475 ) from the Swiss National Science Foundation .

Funding Information:
A.R. is a founder of and equity holder in Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and a scientific advisory board (SAB) member of Syros Pharmaceuticals, ThermoFisher Scientific, Asimov, and NeoGene Therapeutics. A.K.S. has received compensation for consulting for and being on the SAB of Honeycomb Biotechnologies, Cellarity, Cogen Therapeutics, and Dahlia Biosciences. O.R.R., A.K.S., and A.R. are co-inventors on patent applications filed by the Broad Institute to inventions relating to single-cell genomics, such as in PCT/US2018/060860 and US provisional application no. 62/745,259. J.W.G. has licensed technologies to Abbott Diagnostics and Danaher and has ownership positions in PDX Pharmaceuticals and Convergent Genomics. He serves as an advisor to New Leaf Ventures and receives private-sector research support from Zeiss, ThermoFisher, Danaher, Micron, PDX Pharmaceuticals, and Quantitative Imaging. C.I.D. receives research support from Bristol-Myers Squibb. S.S. is a consultant for RareCyte, Inc. A.S. is an employee of Johnson & Johnson. S.A.M. has commercial research grants from Johnson & Johnson. P.K.S. is a member of the SAB or board of directors of and has equity in Glencoe Software and RareCyte Inc., which create software and instruments for tissue imaging.

Publisher Copyright:
© 2020

Keywords

  • AI
  • Cancer Moonshot
  • Human Tumor Atlas
  • cancer transitions
  • data integration
  • data visualization
  • metastasis
  • pre-cancer
  • resistance
  • single-cell genomics
  • spatial genomics
  • spatial imaging
  • tumor

Fingerprint

Dive into the research topics of 'The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution'. Together they form a unique fingerprint.

Cite this